Our findings, together with recent data from postmortem brain tissue, reaffirm the importance of the angiotensin hypothesis in AD and indicate that activation of the regulatory ACE2/Ang-(1–7)/MasR rRAS pathway, which works to downregulate the cRAS pathway whilst directly boosting memory and learning, provides an exciting, alternative and novel therapeutic target for potential treatment in AD. Here, ACE2 is linked to Alzheimer disease.